<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462578</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-RELA02-048</org_study_id>
    <secondary_id>2010-022388-37</secondary_id>
    <secondary_id>VZ-MDS-PI-0245</secondary_id>
    <nct_id>NCT01462578</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)</brief_title>
  <acronym>RELAZA2</acronym>
  <official_title>Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of efficacy of azacitidine to prevent a relapse&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analysis of the effectiveness of azacitidine 6 months after start of therapy to prevent a&#xD;
      hematological relapse in MDS or AML patients with significant residuals or an increase of&#xD;
      minimal residual disease (MRD) which is defined as:&#xD;
&#xD;
        -  decrease of CD34 donor chimerism (&lt;80%) after allogeneic related or unrelated HSCT in&#xD;
           CD34+ or CD117+ MDS or AML or&#xD;
&#xD;
        -  increase in the AML-specific molecular markers in the quantitative PCR for t(6,9), NPM1+&#xD;
           AML &gt;1% (ratio to reference gene) after conventional chemotherapy or allogeneic HSCT or&#xD;
&#xD;
        -  persistence of the (above) MRD level &gt;1% after conventional chemotherapy or allogeneic&#xD;
           HSCT&#xD;
&#xD;
        -  tolerance of azacitidine&#xD;
&#xD;
        -  quality of the response of the MRD (major vs. minor) and the relapse-free survival and&#xD;
           overall survival 12, 24 and 30 months after starting treatment with azacitidine&#xD;
&#xD;
        -  modulation of CD34+, NK- and T-cells of MDS and AML patients by azacitidine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2021</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with hematological relapse 6 months after start of treatment with azacitidin</measure>
    <time_frame>6 months after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of occurrence or exacerbation of clinical relevant acute or chronic GvHD</measure>
    <time_frame>2 years follow-up after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with infectious SAEs (rate of SAE)</measure>
    <time_frame>2 years follow-up after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of changes of methylation in CD34+ cells</measure>
    <time_frame>2 years follow-up after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival and overall survival</measure>
    <time_frame>12, 24 and 30 months after start of treatment</time_frame>
    <description>Relapse-free survival and overall survival 12, 24 and 30 months after start of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Acute Myelocytic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Azacytidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacytidine injection: 75 mg/m²/d, subcutaneous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles</description>
    <arm_group_label>Azacytidine</arm_group_label>
    <other_name>Vidaza®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Screening:&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  patients with MDS or AML after conventional chemotherapy or allogeneic HSCT and&#xD;
             positive molecular marker such as t(6,9), NPM1 pos. or CD34+ or CD117+ in the case of&#xD;
             an allogeneic HSCT&#xD;
&#xD;
        Treatment:&#xD;
&#xD;
          -  MDS or AML without haematological relapse (blasts &lt;5% in the bone marrow), and&#xD;
&#xD;
          -  decrease of CD34 donor chimerism (&lt;80%) after allogeneic related or unrelated HSCT in&#xD;
             CD34+ or CD117+ MDS or AML or&#xD;
&#xD;
          -  increase in the AML-specific molecular marker in the quantitative PCR for t(6,9),&#xD;
             NPM1+ AML &gt;1% after conventional chemotherapy or allogeneic HSCT or&#xD;
&#xD;
          -  persistence of the (above) MRD levels &gt;1% (relative to the reference gene) after&#xD;
             conventional chemotherapy or allogeneic HSCT&#xD;
&#xD;
          -  leukocytes &gt; 3 Gpt/l and platelets &gt;75 Gpt/l (transfusion independent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of hypersensitivity to any of the drugs used or their constituents or to&#xD;
             drugs with similar chemical structure,&#xD;
&#xD;
          -  Participation of the patient in another clinical trial within the last 4 weeks before&#xD;
             the inclusion&#xD;
&#xD;
          -  addiction or other disorders that do not allow the concerned person, to assess the&#xD;
             nature and scope and possible consequences in the clinical investigation&#xD;
&#xD;
          -  pregnant or breast feeding women&#xD;
&#xD;
          -  women of childbearing potential, except women who meet the following criteria:&#xD;
&#xD;
               -  post-menopausal (12 months natural amenorrhea or 6 months amenorrhea with serum&#xD;
                  FSH &gt;40 U/ml)&#xD;
&#xD;
               -  postoperative (6 weeks after hysterectomy with or without bilateral ovariectomy )&#xD;
&#xD;
               -  regular and proper use of a contraceptive method with error rate &lt;1% per year&#xD;
                  (e.g., implants, depot injections, oral contraceptives, intrauterine device, IUD)&#xD;
                  during study treatment and up to 1 year after completion of therapy&#xD;
&#xD;
               -  sexual abstinence during study treatment and up to 1 year after completion of&#xD;
                  therapy&#xD;
&#xD;
               -  Vasectomy of the partner&#xD;
&#xD;
          -  Men who do not use one of the following types of effective contraception during study&#xD;
             treatment and up to 1 year after completion of therapy:&#xD;
&#xD;
               -  sexual abstinence&#xD;
&#xD;
               -  State post-vasectomy&#xD;
&#xD;
               -  Condom&#xD;
&#xD;
          -  Evidence that the participating person is not expected to comply with the protocol&#xD;
             (such as lack of cooperation)&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Severe hepatic impairment (AST and ALT may not exceed three times the normal) or liver&#xD;
             cirrhosis or malignant liver tumor&#xD;
&#xD;
          -  Dialysis dependent renal dysfunction&#xD;
&#xD;
          -  Known severe congestive heart failure, incidence of clinically unstable cardiac or&#xD;
             pulmonary disease These criteria are not for the screening phase up to a known&#xD;
             allergic reaction to azacitidine or intolerance to apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, 01307 Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz (Küchwald)</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Hämatologie (Westdeutsches Tumorzentrum)</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität, Medizinische Klinik II Hämatologie / Onkologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Medizinische Klinik, Abt. Innere Medizin V</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München, III. Med. Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU München, Klinikum Großhadern, Med. Klinik III</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Innere Medizin A - KMT-Zentrum</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sal-aml.org</url>
    <description>Website Study Alliance Leukemia (coordinating study group)</description>
  </link>
  <results_reference>
    <citation>Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12.</citation>
    <PMID>30442503</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>October 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2011</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms benign, malignant and unspecified</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

